5fog: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of hte Cryptosporidium muris cytosolic leucyl-tRNA synthetase editing domain complex with a post-transfer editing analogue of norvaline (Nv2AA)== | ==Crystal structure of hte Cryptosporidium muris cytosolic leucyl-tRNA synthetase editing domain complex with a post-transfer editing analogue of norvaline (Nv2AA)== | ||
<StructureSection load='5fog' size='340' side='right' caption='[[5fog]], [[Resolution|resolution]] 2.30Å' scene=''> | <StructureSection load='5fog' size='340' side='right'caption='[[5fog]], [[Resolution|resolution]] 2.30Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5fog]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FOG OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[5fog]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Cryptosporidium_muris_RN66 Cryptosporidium muris RN66]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FOG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5FOG FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=VRT:2-(L-NORVALYL)AMINO-2-DEOXYADENOSINE'>VRT</scene | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=VRT:2-(L-NORVALYL)AMINO-2-DEOXYADENOSINE'>VRT</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5fog FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fog OCA], [https://pdbe.org/5fog PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5fog RCSB], [https://www.ebi.ac.uk/pdbsum/5fog PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5fog ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | |||
[https://www.uniprot.org/uniprot/B6AA20_CRYMR B6AA20_CRYMR] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The apicomplexan parasites Cryptosporidium and Toxoplasma are serious threats to human health. Cryptosporidiosis is a severe diarrheal disease in malnourished children and immunocompromised individuals, with the only FDA approved drug treatment currently being nitazoxanide. The existing therapies for toxoplasmosis, an important pathology in immunocompromised individuals and pregnant women, also have serious limitations. With the aim of developing alternative therapeutic options to address these health problems, we tested a number of benzoxaboroles, boron-containing compounds shown to be active against various infectious agents, for growth inhibition of Cryptosporidium parasites in mammalian cells. A 3-aminomethyl benzoxaborole, AN6426, with activity in the micromolar range and comparable to nitazoxanide, was identified and further characterised using biophysical measurements of affinity and crystal structures of complexes with the editing domain of Cryptosporidium leucyl-tRNA synthetase (LeuRS). The same compound was shown to be active against Toxoplasma parasites, with the activity being enhanced in the presence of norvaline, an amino acid that can be mischarged by LeuRS. Our observations are consistent with AN6426 inhibiting protein synthesis in both Cryptosporidium and Toxoplasma by forming a covalent adduct with tRNALeu in the LeuRS editing active site, which suggest that further exploitation of the benzoxaboroles scaffold is a valid strategy to develop novel, much needed antiparasitic agents. | |||
Cryptosporidium and Toxoplasma parasites are inhibited by a benzoxaborole targeting leucyl-tRNA synthetase.,Palencia A, Liu RJ, Lukarska M, Gut J, Bougdour A, Touquet B, Wang ED, Li X, Alley MR, Freund YR, Rosenthal PJ, Hakimi MA, Cusack S Antimicrob Agents Chemother. 2016 Jul 18. pii: AAC.00873-16. PMID:27431220<ref>PMID:27431220</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 5fog" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Aminoacyl tRNA synthetase 3D structures|Aminoacyl tRNA synthetase 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Cryptosporidium muris RN66]] | ||
[[Category: Alley | [[Category: Large Structures]] | ||
[[Category: Bougdour | [[Category: Alley MRK]] | ||
[[Category: Cusack | [[Category: Bougdour A]] | ||
[[Category: Gut | [[Category: Cusack S]] | ||
[[Category: Hakimi | [[Category: Gut J]] | ||
[[Category: Liu | [[Category: Hakimi MA]] | ||
[[Category: Lukarska | [[Category: Liu RJ]] | ||
[[Category: Palencia | [[Category: Lukarska M]] | ||
[[Category: Rosenthal | [[Category: Palencia A]] | ||
[[Category: Touquet | [[Category: Rosenthal PJ]] | ||
[[Category: Wang | [[Category: Touquet B]] | ||
[[Category: Wang ED]] | |||